EVOTEC SE ADR 1/2 O.N. Cash Flow Conversion Efficiency
EVOTEC SE ADR 1/2 O.N. cash flow conversion efficiency. Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€63.63 Million ≈ $74.39 Million USD) by net assets (€813.70 Million ≈ $951.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of EVOTEC SE ADR 1/2 O.N. (2021–2025)
Cash flow conversion efficiency of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025. This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View EVOTEC SE ADR 1/2 O.N. share price for real-time trading data and today's change.
EVOTEC SE ADR 1/2 O.N. Cash Flow Conversion Ratio Explained
EVOTEC SE ADR 1/2 O.N. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
EVOTEC SE ADR 1/2 O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their cash flow conversion efficiency. Also see EVOTEC SE ADR 1/2 O.N. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu General Science Tech
SHG:601500
|
0.094x |
|
NatureCell Co.Ltd
KQ:007390
|
-0.052x |
|
Shen Ma Industry Co Ltd
SHG:600810
|
0.024x |
|
Precision Wires India Limited
NSE:PRECWIRE
|
0.131x |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
-0.023x |
|
Kornit Digital Ltd
NASDAQ:KRNT
|
0.009x |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
0.030x |
|
Six Flags Entertainment Corporation
NYSE:FUN
|
1.331x |
Annual Cash Flow Conversion Efficiency for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025. Review EVOTEC SE ADR 1/2 O.N. (EVTA) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €813.70 Million ≈ $951.31 Million |
€-9.18 Million ≈ $-10.73 Million |
-0.011x | -158.97% |
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -81.23% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€205.81 Million ≈ $240.61 Million |
0.173x | +88.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€126.60 Million ≈ $148.01 Million |
0.092x | -- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more